Form 4: Bridgette Heller Sells Dexcom Shares Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
Director Bridgette P. Heller of Dexcom Inc. has sold 1,012 shares of common stock for $60.01 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Bridgette P. Heller, a Director at Dexcom Inc. (DXCM), reported a transaction on May 12, 2026.
- She sold 1,012 shares of common stock.
- The sale was executed at a price of $60.01 per share.
- This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted on August 14, 2025, which allows for the orderly disposition of shares.
- Following the transaction, Ms. Heller beneficially owns 25,007 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider stock sale executed under a pre-arranged 10b5-1 plan, which is a common and accepted practice.
Negatives
- Director Bridgette P. Heller sold 1,012 shares of Dexcom Inc. common stock.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan indicates a pre-planned disposition strategy, often employed by executives to avoid concerns about insider trading while managing their stock holdings.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| 10b5-1 Plan Adoption | Director Bridgette P. Heller adopted a Rule 10b5-1(c) trading plan to facilitate the orderly disposition of her Dexcom Inc. shares. | 08/14/2025 | Provides a structured and compliant method for the director to sell shares, mitigating potential insider trading concerns. |
Stakeholder Impact
- Shareholders: The sale of shares by a director may be perceived by some shareholders as a negative signal, although the use of a 10b5-1 plan mitigates this concern by indicating a pre-planned disposition rather than a reaction to non-public information.
Key Dates
| Date | Description |
|---|---|
| 08/14/2025 | Date Ms. Heller adopted a 10b5-1 Plan. |
| 05/12/2026 | Earliest transaction date and transaction date for the sale of common stock. |
| 05/14/2026 | Date the form was signed by the attorney-in-fact. |
Keywords
Dexcom Inc., DXCM, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Director Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.